

Discontinuation Announcement MEDRAD® Mark V ProVis Angiographic Syringe Kits 150-FT-Q, 200 FT-Q

March 20, 2025

Bayer Medical Care Inc. 1 Bayer Drive Indianola, PA 15051 U.S.A.

(412) 767-2400

www.ri.bayer.com

Dear Valued Bayer Partner,

We deeply value the trust you place in the MEDRAD® Mark V ProVis for your patient care needs. As technology and innovation continue to progress, it becomes increasingly challenging to source replacement parts for earlier generations of equipment. This, in turn, affects our ability to maintain the high standards of service that Bayer is committed to providing.

Bayer plans to continue to accept orders for the MEDRAD® Mark V ProVis Angiographic syringe kits up **until December 29th, 2025**, with the **final ship date of December 31st**, 2025, unless inventory is not available.

Impacted product includes:

- 150mL FasTurn Syringe Kit (150-FT-Q)
- 200mL FasTurn Syringe Kit (200-FT-Q)

Bayer recognizes the evolving demands and requirements you face in your imaging environment amidst today's heightened workload and labor shortages. Bayer is committed to your success, and we are here to support your asset management plan, including the transition to the MEDRAD® Mark 7 Arterion Injection System, which provides access to Bayer's clinical and technical expertise, tailored training, and ongoing education in line with your departmental goals. Flexible upgrade pathways are available for discussion with your Bayer representative, who is ready to explore replacement solutions and discuss how the performance, capability, and reliability of the MEDRAD® Mark 7 Arterion, paired with comprehensive service, can improve your workflow. Together we will ensure a seamless transition to meet the evolving needs to power patient care.

Please contact your Bayer Channel Management Representative, or appropriate Bayer Customer Support Representavtive at 1-800-633-7231 (Option 2), or visit www.radiologysolutions.bayer.com if you have questions regarding the discontinuation of this syringe product or availability of the MEDRAD® Mark 7 Arterion Injection System.

Sincerely,

Jill Carbone

Jel. Calone

Head, US Product & Pipeline - Radiology